Delivery Order SPE2DB20D9127-SPE2DB24FPRG9
Award Date
8/30/24
Potential Completion Date
9/23/24
Potential Value
$55K
Federal Agency
Defense Logistics Agency
Awardee
DMS Pharmaceutical Group Inc.
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $78,899.37 and has an ultimate completion date of April 11, 2023. The contract is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS, a 5 ML vial. This award is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $82,844.34, is for the delivery of 3,750 units of the 5 ML vial pharmaceutical product ASPARLAS, with a completion date of December 30, 2024. DMS Pharmaceutical Group holds a larger single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $27,614.78, is for the delivery of 3,750 units of the drug ASPARLAS (5 mL vials) with a completion date of May 17, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the provision of 3,750 units of the drug ASPARLAS (5 ML vial) with a ceiling value of $82,844.34. This delivery order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999, which allows the DLA to issue delivery orders...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business. The contract has a ceiling value of $138,073.90 and an ultimate completion date of May 29, 2024. DMS Pharmaceutical Group will provide 3,750 units of the pharmaceutical product ASPARLAS (5 ML vial) to support the recurring medical supply needs of military health facilities. This delivery order is part of a larger indefinite delivery...
This is a firm fixed-price delivery order awarded to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) under the SPE2DB program. The award, valued at $55,229.58, is for the delivery of 3,750 units of the pharmaceutical product ASPARLAS (5 mL vial). This order is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This IDC allows the DLA to...
This is a delivery order award to DMS Pharmaceutical Group Inc., a woman-owned small business, by the Defense Logistics Agency (DLA) for the procurement of 3,750 units of the pharmaceutical product ASPARLAS (5 mL vial). The $105,199.16 firm fixed-price delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract (IDC) with the DLA valued at $499,999,999. This IDC, valid through November 2026, enables the DLA to issue delivery orders for a broad range of...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The order, valued at $27,614.78, is for the delivery of 3,750 units of the drug Asparlas in 5 mL vials. The order is a firm fixed-price contract with a completion date of May 23, 2024. The award is associated with a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA....
This contract award to DMS Pharmaceutical Group Inc., a woman-owned small business, is for the delivery of 3,750 units of the drug ASPARLAS (3,750 unit/5 ML vial) to the U.S. Department of Defense's Medical Supply Chain. The firm-fixed-price delivery order, valued at $27,614.78, is part of a larger indefinite delivery contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program. This single-award IDC, valued up to $499,999,999, allows the DLA to issue delivery orders to DMS...
This federal contract was awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $52,599.60, is a delivery order under the SPE2DB program, which is a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group worth up to $499,999,999 and valid through November 2026. The contract is for the supply of 3,750 units of the pharmaceutical product ASPARLAS,...